Jacobs Levy Equity Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.76M | Sell |
17,674
-135,296
| -88% | -$44.1M | 0.02% | 401 |
|
|
2025
Q1 | $41.3M | Buy |
+152,970
| New | +$41.3M | 0.16% | 137 |
|
|
2024
Q3 | – | Sell |
-13,283
| Closed | -$3.23M | – | 946 |
|
|
2024
Q2 | $3.23M | Sell |
13,283
-113,084
| -89% | -$27.5M | 0.01% | 513 |
|
|
2024
Q1 | $18.9M | Buy |
+126,367
| New | +$18.9M | 0.08% | 214 |
|
|
2022
Q3 | – | Sell |
-8,604
| Closed | -$1.26M | – | 983 |
|
|
2022
Q2 | $1.26M | Sell |
8,604
-22,670
| -72% | -$3.31M | 0.01% | 698 |
|
|
2022
Q1 | $5.11M | Sell |
31,274
-36,472
| -54% | -$5.96M | 0.03% | 414 |
|
|
2021
Q4 | $11.5M | Buy |
+67,746
| New | +$11.5M | 0.08% | 274 |
|
|
2021
Q3 | – | Sell |
-1,525
| Closed | -$259K | – | 1031 |
|
|
2021
Q2 | $259K | Sell |
1,525
-6,777
| -82% | -$1.15M | ﹤0.01% | 948 |
|
|
2021
Q1 | $1.17M | Sell |
8,302
-710
| -8% | -$100K | 0.01% | 706 |
|
|
2020
Q4 | $1.17M | Buy |
9,012
+2,259
| +33% | +$294K | 0.01% | 682 |
|
|
2020
Q3 | $983K | Buy |
+6,753
| New | +$983K | 0.01% | 669 |
|
|
2019
Q4 | – | Sell |
-102,590
| Closed | -$8.25M | – | 990 |
|
|
2019
Q3 | $8.25M | Buy |
+102,590
| New | +$8.25M | 0.1% | 246 |
|
|
2017
Q1 | – | Sell |
-12,100
| Closed | -$453K | – | 912 |
|
|
2016
Q4 | $453K | Buy |
+12,100
| New | +$453K | 0.01% | 694 |
|
|
2016
Q3 | – | Sell |
-25,061
| Closed | -$1.39M | – | 1009 |
|
|
2016
Q2 | $1.39M | Sell |
25,061
-138,530
| -85% | -$7.69M | 0.03% | 499 |
|
|
2016
Q1 | $10.3M | Buy |
+163,591
| New | +$10.3M | 0.22% | 137 |
|
|
2015
Q3 | – | Sell |
-3,940
| Closed | -$472K | – | 800 |
|
|
2015
Q2 | $472K | Sell |
3,940
-3,500
| -47% | -$419K | 0.01% | 578 |
|
|
2015
Q1 | $777K | Buy |
+7,440
| New | +$777K | 0.01% | 529 |
|